Desktop Genetics Ltd
announced today that it has received investment funding from Illumina,
Inc. ILMN, the global leader in next-generation sequencing
(NGS) technology. The investment will be used to fund the continued
development and commercialization of the DESKGEN platform with a
particular focus on integration with NGS pipelines.
The investment from Illumina follows DTG's recent fundraising from a
syndicate of venture capitalists and angel investors. This combined
funding is being used to continue developing DTG's proprietary DESKGEN
genome editing software platform and core CRISPR algorithms. DTG is also
investing in the expansion of its existing sales
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in